What is Zacks Research's Forecast for Clorox Q1 Earnings?

The Clorox Company (NYSE:CLX - Free Report) - Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Clorox in a research report issued to clients and investors on Wednesday, November 13th. Zacks Research analyst R. Lohia now forecasts that the company will post earnings per share of $1.75 for the quarter, up from their prior forecast of $1.41. The consensus estimate for Clorox's current full-year earnings is $6.85 per share.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.50. The firm had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The company's revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 earnings per share.

A number of other analysts have also recently weighed in on the company. Jefferies Financial Group raised Clorox from a "hold" rating to a "buy" rating and boosted their price target for the stock from $174.00 to $187.00 in a research report on Tuesday, October 1st. Citigroup boosted their target price on shares of Clorox from $165.00 to $170.00 and gave the stock a "neutral" rating in a research report on Friday, September 6th. DA Davidson raised their price target on Clorox from $153.00 to $171.00 and gave the company a "neutral" rating in a research report on Monday, November 4th. BNP Paribas raised Clorox to a "strong sell" rating in a research report on Friday, September 6th. Finally, Barclays raised their target price on Clorox from $137.00 to $139.00 and gave the company an "underweight" rating in a report on Friday, November 1st. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $155.00.

Clorox Stock Up 0.9 %

Shares of CLX stock traded up $1.50 on Monday, hitting $169.14. The company's stock had a trading volume of 1,363,899 shares, compared to its average volume of 1,242,923. The stock has a market capitalization of $20.94 billion, a price-to-earnings ratio of 58.93, a P/E/G ratio of 3.10 and a beta of 0.41. Clorox has a fifty-two week low of $127.60 and a fifty-two week high of $169.21. The firm's fifty day moving average price is $162.53 and its 200-day moving average price is $147.73. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd were issued a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend was Wednesday, October 23rd. Clorox's dividend payout ratio is 170.03%.

Insider Buying and Selling at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the company's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares of the company's stock, valued at $2,229,719.92. This represents a 11.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.57% of the company's stock.

Institutional Trading of Clorox

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLX. Toronto Dominion Bank boosted its stake in shares of Clorox by 8.3% in the 3rd quarter. Toronto Dominion Bank now owns 65,744 shares of the company's stock valued at $10,710,000 after purchasing an additional 5,051 shares during the last quarter. Coldstream Capital Management Inc. lifted its holdings in Clorox by 128.5% in the third quarter. Coldstream Capital Management Inc. now owns 3,626 shares of the company's stock valued at $595,000 after buying an additional 2,039 shares during the period. Geode Capital Management LLC lifted its holdings in Clorox by 1.1% in the third quarter. Geode Capital Management LLC now owns 3,028,333 shares of the company's stock valued at $491,713,000 after buying an additional 33,970 shares during the period. M&T Bank Corp boosted its stake in Clorox by 0.9% in the third quarter. M&T Bank Corp now owns 30,858 shares of the company's stock valued at $5,027,000 after acquiring an additional 287 shares during the last quarter. Finally, Continuum Advisory LLC grew its holdings in Clorox by 300.0% during the 3rd quarter. Continuum Advisory LLC now owns 184 shares of the company's stock worth $30,000 after acquiring an additional 138 shares during the period. 78.53% of the stock is currently owned by institutional investors and hedge funds.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.